DK524788D0 - APPLICATION OF MORPHINE ANTAGONISTS FOR THE PREPARATION OF IMMUNO MODULATING AND ANTIVIRAL EFFECTS, IN PARTICULAR FOR TREATMENT OF ACQUIRED IMMUNDEFECT CONDITIONS - Google Patents

APPLICATION OF MORPHINE ANTAGONISTS FOR THE PREPARATION OF IMMUNO MODULATING AND ANTIVIRAL EFFECTS, IN PARTICULAR FOR TREATMENT OF ACQUIRED IMMUNDEFECT CONDITIONS

Info

Publication number
DK524788D0
DK524788D0 DK524788A DK524788A DK524788D0 DK 524788 D0 DK524788 D0 DK 524788D0 DK 524788 A DK524788 A DK 524788A DK 524788 A DK524788 A DK 524788A DK 524788 D0 DK524788 D0 DK 524788D0
Authority
DK
Denmark
Prior art keywords
preparation
treatment
acquired
immundefect
conditions
Prior art date
Application number
DK524788A
Other languages
Danish (da)
Other versions
DK524788A (en
Inventor
Marc Yves Franck Clemen Shelly
Original Assignee
Marc Yves Franck Clemen Shelly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marc Yves Franck Clemen Shelly filed Critical Marc Yves Franck Clemen Shelly
Publication of DK524788D0 publication Critical patent/DK524788D0/en
Publication of DK524788A publication Critical patent/DK524788A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utilization of morphine antagonists, such as Naltrexone, beta-endorphine 1-27, or their derivatives or analogs, in the preparation of an immunomodulator and/or antiviral drug for the treatment of acquired immunodeficiency states, particularly the infection by HIV.
DK524788A 1987-01-21 1988-09-21 APPLICATION OF MORPHINE ANTAGONISTS FOR THE PREPARATION OF IMMUNO MODULATING AND ANTIVIRAL EFFECTS, IN PARTICULAR FOR TREATMENT OF ACQUIRED IMMUNDEFECT CONDITIONS DK524788A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8700670A FR2609632B1 (en) 1987-01-21 1987-01-21 NOVEL THERAPEUTIC APPLICATION OF 17- (CYCLOPROPYLMETHYL) -4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE AND PHARMACEUTICAL COMPOSITIONS FOR THIS USE
PCT/FR1988/000032 WO1988005297A1 (en) 1987-01-21 1988-01-21 Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states

Publications (2)

Publication Number Publication Date
DK524788D0 true DK524788D0 (en) 1988-09-21
DK524788A DK524788A (en) 1988-11-18

Family

ID=9347124

Family Applications (1)

Application Number Title Priority Date Filing Date
DK524788A DK524788A (en) 1987-01-21 1988-09-21 APPLICATION OF MORPHINE ANTAGONISTS FOR THE PREPARATION OF IMMUNO MODULATING AND ANTIVIRAL EFFECTS, IN PARTICULAR FOR TREATMENT OF ACQUIRED IMMUNDEFECT CONDITIONS

Country Status (9)

Country Link
EP (1) EP0278821B1 (en)
JP (1) JPH02502278A (en)
AT (1) ATE112488T1 (en)
AU (1) AU610561B2 (en)
DE (1) DE3851711D1 (en)
DK (1) DK524788A (en)
FR (1) FR2609632B1 (en)
OA (1) OA09124A (en)
WO (1) WO1988005297A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
US4877791A (en) * 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
RU2058553C1 (en) * 1994-03-18 1996-04-20 Иван Николаевич Головистиков Method of estimation of human immune status suppressive link
RU2056852C1 (en) * 1994-03-18 1996-03-27 Иван Николаевич Головистиков Agent for treatment of autoimmune diseases with suppressor immunodeficiency and a method of autoimmune diseases treatment
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
CA2478558C (en) * 2002-03-14 2012-09-11 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
EP1615646B2 (en) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
JP5241484B2 (en) 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ Use of opioid antagonists to attenuate endothelial cell proliferation and endothelial cell migration
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
TWI553009B (en) 2007-03-29 2016-10-11 普吉尼製藥公司 Peripheral opioid receptor antagonists and uses thereof
PL2565195T3 (en) 2007-03-29 2015-10-30 Wyeth Llc Peripheral opioid receptor and antagonists and uses thereof
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
KR101581480B1 (en) 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response
US11285192B2 (en) 2019-03-13 2022-03-29 Adamis Pharmaceuticals Corporation Formulation including a combination of beta-endorphin and adrenocorticotropic hormone
MX2021010989A (en) * 2019-03-13 2021-10-01 Adamis Pharmaceuticals Corp Formulation including a combination of î²-endorphin and adrenocorticotropic hormone.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives

Also Published As

Publication number Publication date
EP0278821A1 (en) 1988-08-17
AU1189688A (en) 1988-08-10
ATE112488T1 (en) 1994-10-15
FR2609632B1 (en) 1991-03-29
EP0278821B1 (en) 1994-10-05
WO1988005297A1 (en) 1988-07-28
AU610561B2 (en) 1991-05-23
JPH02502278A (en) 1990-07-26
DK524788A (en) 1988-11-18
DE3851711D1 (en) 1994-11-10
FR2609632A1 (en) 1988-07-22
OA09124A (en) 1991-10-31

Similar Documents

Publication Publication Date Title
DK524788D0 (en) APPLICATION OF MORPHINE ANTAGONISTS FOR THE PREPARATION OF IMMUNO MODULATING AND ANTIVIRAL EFFECTS, IN PARTICULAR FOR TREATMENT OF ACQUIRED IMMUNDEFECT CONDITIONS
DK0509019T3 (en) Treatment of human retroviral infections with 2 ', 3'-dideoxyinosine
DK162965C (en) APPLICATION OF A DIFLUORNUCLEOSIDE OR A PHARMACEUTICAL ACCEPTABLE SALT THEREOF FOR THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF NEOPLASMA
ES2149267T3 (en) SUBSTITUTED CYCLIC CARBONYLL AND DERIVED FROM THE SAME USEFUL AS RETROVIRAL PROTEASE INHIBITORS.
ES2130114T3 (en) 5,11-DIHIDRO-6H-DIPIRIDO (3,2-B: 2 ', 3'-E) (1,4) DIAZEPINES AND ITS USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION.
DK336688A (en) NUCLEOSIDES WITHOUT PROCEDURE FOR PREPARING THEREOF
DK92788A (en) USE OF 3'-DEOXY-3'-FLUORUANOSIDES FOR THE PREPARATION OF MEDICINAL PRODUCTS AGAINST RETROVIRA
ZA913033B (en) N-(3-fluoro-2-phosphonylmethoxypropyl)derivatives of purine and pyrimidine heterocyclic basis,their preparation and use
DE3780016D1 (en) PHARMACEUTICAL PREPARATION WITH 3'-DESOXYTHYMIDIN-2'-EN (3'-DESOXY-2 ', 3'-DIDEHYDROTHYMIDINE) FOR TREATING PATIENTS WITH RETROVIRAL INFECTIONS.
DK422589A (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF IMMUNE DEFECTIVE CONDITIONS
DK538888D0 (en) USE OF CASTANOSPERMINESTERS FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION
TW371662B (en) Antiviral acyclic phosphonomethoxyalkyl substituted alkenyl purine and pyrimidine derivatives
ATE108335T1 (en) KIT OR COMPOSITION FOR THE PREVENTION OR TREATMENT OF HIV-1 INFECTION.
IT1225262B (en) METHOD FOR THE AWARENESS OF SMALL ANIMALS TO VIRUS INFECTION OF HUMAN IMMUNODEFICIENCY (HIV)
ES2066897T3 (en) 5,11-DIHYDRO-6H-PIRIDO (2,3-B) (1,4) BENZODIAZEPIN-6-ONAS AND -TIONAS AND THEIR USE IN THE PREVENTION OR TREATMENT OF AIDS.
ATE87482T1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CEREBRAL PSYCHO-ORGANIC SYNDROMES.
PT99962A (en) USING ANTI-DEPRESSING MEDICINE
IT8622051A0 (en) PHARMACEUTICAL COMPOSITIONS HEALING ADAPTIVITY.
DK469487D0 (en) PHARMACEUTICAL TREATMENT MEDICINE
FI862413A0 (en) TORKNINGSGRUPP MED ENKEL VIRA FOER PAPPERSMASKIN.
FI862412A (en) ANORDNING FOER OMRAODET AV DRAGET MED ANKEL VIRA I FLERCYLINDERTORKEN AV EN PAPPERSMASKIN.
ATE79529T1 (en) DEVICE FOR THE STIMULATION OF LIMB ARRANGEMENTS.
ATE108654T1 (en) ANTI-HIV COMPOSITIONS.
IT8720402A0 (en) PROCEDURE FOR THE PREPARATION OF CONDENSED AS-TRIAZINE DERIVATIVES.
ES1011413Y (en) TABLE SET.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment